$1.58
0.63% day before yesterday
Nasdaq, Nov 28, 09:30 pm CET
ISIN
US00972D1054
Symbol
AKBA

Akebia Therapeutics, Inc. Stock price

$1.58
-1.51 48.87% 1M
-1.30 45.14% 6M
-0.32 16.84% YTD
-0.48 23.30% 1Y
+1.33 529.73% 3Y
-1.73 52.27% 5Y
-9.15 85.27% 10Y
-25.12 94.08% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-0.01 0.63%
ISIN
US00972D1054
Symbol
AKBA
Industry

Key metrics

Basic
Market capitalization
$419.3m
Enterprise Value
$444.8m
Net debt
$25.5m
Cash
$166.4m
Shares outstanding
265.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.9 | 1.7
EV/Sales
2.0 | 1.8
EV/FCF
13.8
P/B
10.1
Financial Health
Equity Ratio
-22.3%
Return on Equity
141.1%
ROCE
8.7%
ROIC
11.4%
Debt/Equity
4.6
Financials (TTM | estimate)
Revenue
$225.1m | $245.7m
EBITDA
$29.2m | -
EBIT
$20.1m | $32.6m
Net Income
$-15.9m | $-680.0k
Free Cash Flow
$32.2m
Growth (TTM | estimate)
Revenue
32.5% | 53.4%
EBITDA
627.2% | -
EBIT
162.9% | 170.5%
Net Income
65.4% | 99.0%
Free Cash Flow
183.5%
Margin (TTM | estimate)
Gross
82.5%
EBITDA
13.0% | -
EBIT
9.0%
Net
-7.1% | -0.3%
Free Cash Flow
14.3%
More
EPS
$-0.1
FCF per Share
$0.1
Short interest
13.5%
Employees
181
Rev per Employee
$880.0k
Show more

Is Akebia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Akebia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Akebia Therapeutics, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Akebia Therapeutics, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Akebia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
225 225
32% 32%
100%
- Direct Costs 39 39
52% 52%
17%
186 186
29% 29%
83%
- Selling and Administrative Expenses 109 109
5% 5%
48%
- Research and Development Expense 48 48
33% 33%
21%
29 29
627% 627%
13%
- Depreciation and Amortization 9.01 9.01
75% 75%
4%
EBIT (Operating Income) EBIT 20 20
163% 163%
9%
Net Profit -16 -16
65% 65%
-7%

In millions USD.

Don't miss a Thing! We will send you all news about Akebia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akebia Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2 at 4:30 PM EST.
Neutral
Seeking Alpha
19 days ago
Akebia Therapeutics, Inc. ( AKBA ) Q3 2025 Earnings Call November 10, 2025 8:00 AM EST Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate Communications John Butler - CEO, President & Director Nicholas Grund - Senior VP & Chief Commercial Officer Erik Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer Conference Call Participants Roanna Clarissa Ruiz - ...
Neutral
GlobeNewsWire
19 days ago
Vafseo® (vadadustat) Q3 2025 net product revenues grew to  $14.3 million ; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter; Access for 275,000 total patients across customer base expected by year-end Vadadustat post-hoc data analysis presented at ASN Kidney Week demonstrates composite of all-cause mortality a...
More Akebia Therapeutics, Inc. News

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO John Butler
Employees 181
Founded 2007
Website akebia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today